Gene-Silencing for Treatment of Cardiovascular Diseases

Nolte, Andrea; Schneider, Martin; Walker, Tobias; Wendel, Hans-Peter

doi:10.5772/10659

Cited by 3 publications

(6 citation statements)

References 73 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presented therapeutic techniques indicate the effectiveness of siRNA as a potential tool to reshape RAS-system. Following that, Merril 35 , proposed therapy based on temporarily silencing ACE2 expression by designing specific siRNA molecules, this would effectively block the viral entry by modulating immune system to efficiently prevent from viral infection.…”

Section: Therapeutic Modalities For Sars-cov-2 Infection Protease Inhmentioning

confidence: 99%

Therapeutic Modalities for Sars-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells

Qamar¹,

Basharat²,

Bilal³

et al. 2020

J Pure Appl Microbiol

View full text Add to dashboard Cite

An acute respiratory disease (SARS-CoV-2, also recognized as COVID-19/2019-nCoV), caused by nCoV created a worldwide emergency. The World Health Organization declared the SARS-CoV-2 as epidemic of international concern on January 2020. After SARS-CoV in 2002 and MERS-CoV in 2012, the emergence of SARS-CoV-2 is marked as third highly pathogenic coronavirus of 21st century. Till now, various researches have been conducted, highlighting SARS-CoV-2 as β-coronavirus with high phylogenetic and genomic similarity with bat-CoV, indicating bats as natural reservoir of coronaviruses. It has also been confirmed that SARS-CoV-2 uses the same (ACE2) receptor for host cellular entry as of SARS-CoV, and primarily spread through respiratory pathway. Evidences shows continuous human-to-human viral transfer, with numerous worldwide exported cases. Currently, there is no specific approved drug available for the treatment of SARS-CoV-2, but various anti-parasitic and anti-viral drugs are being investigated. In this review, we have described several possible therapeutic modalities for SARS-CoV-2 infection based on (i) host protease inhibitors to block viral entry into the cell; (ii) gene silencing using siRNA-based RNAi and (iii) type I interferons (IFN1)-based therapeutics have been discussed in detail. Background knowledge on these strategies highlight them as potential therapeutic targets, which could be evaluated on urgent basis to combat COVID-19 epidemic.

show abstract

Section: Therapeutic Modalities For Sars-cov-2 Infection Protease Inhmentioning

confidence: 99%

Therapeutic Modalities for Sars-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells

Qamar¹,

Basharat²,

Bilal³

et al. 2020

J Pure Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…Thus gene silencing occurs, and receptor protein is not synthesized. Activated RISC becomes free to further destroy mRNA (Nolte et al, 2011 ; Koenig et al, 2013 ).…”

Section: Nanotechnology-based Oral Delivery Of Antihypertensivementioning

confidence: 99%

“…siRNA effect was also seen in α1D-adrenergic receptor. The protein level of which was decreased by using siRNA (Nolte et al, 2011 ; Koenig et al, 2013 ). These studies show promising approach using siRNA for treatment of hypertension.…”

Section: Nanotechnology-based Oral Delivery Of Antihypertensivementioning

confidence: 99%

“…Intravenous route is mostly used for the delivery of SiRNA in treating hypertension. Incorporation of SiRNA in delivery system is required to prevent their degradation by exonuclease activity present in blood (Nolte et al, 2011 ; McLendon et al, 2015 ). Oral delivery has been rarely studied for the delivery of SiRNA for the treatment of hypertension.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanocarriers as treatment modalities for hypertension

et al. 2017

View full text Add to dashboard Cite

Hypertension, a worldwide epidemic at present, is not a disease in itself rather it is an important risk factor for serious cardiovascular disorders including myocardial infarction, stroke, heart failure, and peripheral artery disease. Though numerous drugs acting via different mechanism of action are available in the market as conventional formulations for the treatment of hypertension but they face substantial challenges regarding their bioavailability, dosing and associated adverse effects which greatly limit their therapeutic efficacies. Various studies have demonstrated that nanocarriers can significantly increase the drug bioavailability thereby reducing the frequency of dosing in addition to minimizing toxicity associated with high dose of the drug. The present review provides an insight into the challenges associated with the conventional antihypertensive formulations and need for oral nanoparticulate systems in order to overcome problems associated with conventional formulations. Hypertension has circadian pattern of blood pressure, therefore chronotherapeutics can play a decisive role for the treatment, and however, nanoparticulate system can play major role in hypertension management. Future prospective for particulate nanocarriers in drug delivery for hypertension includes chronotherapeutics and emerging technique like gene therapy which is also covered in the review.

show abstract

“…Here, new blood vessels are built behind the retina leading to a loss of function of the tissues around the macula lutea to the point of loss of vision. The intraocular delivery by injection of siRNA Bevasiranib (Acuity Pharmaceuticals), targeting VEGF, demonstrated great potential for inhibiting neovascularization as well as Ranibizumab (Merck-Sirna therapeutics) also known as Sirna-027/AGN211745 [ 127 ]. Respiratory diseases, induced by virus infections, seem predestined for local delivery of siRNA drugs due to the possibility of simple intranasal application.…”

Section: Local Delivery Systemsmentioning

confidence: 99%

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

et al. 2013

View full text Add to dashboard Cite

Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future.

show abstract

Gene-Silencing for Treatment of Cardiovascular Diseases

Cited by 3 publications

References 73 publications

Therapeutic Modalities for Sars-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells

Therapeutic Modalities for Sars-Cov-2 (Covid-19): Current Status and Role of Protease Inhibitors to Block Viral Entry Into Host Cells

Nanocarriers as treatment modalities for hypertension

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

Contact Info

Product

Resources

About